# A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

> **NCT07668752** · PHASE3 · RECRUITING · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 300 (estimated)

## Conditions studied

- KRAS G12D Mutation
- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** GFH375
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07668752
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2030-06-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668752, "A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*